Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Battelle said that it’s partnering with the Feinstein Institute to develop a novel “neural tourniquet” designed to staunch blood loss using neurostimulation.
The device functions by electrically stimulating neural pathways to the spleen, which prepares platelets in the blood for clotting in the event of a wound, Battelle said. Applications anticipated for the device include pre-operative hospital use, as a wearable device for first responders and soldiers on the battlefield. The device is slated to be enter the market in the next 3-5 years, Battelle added. Read more
Bigfoot Biomedical is making strides towards its goal of a bionic pancreas after inking a deal with Dexcom Inc., maker of continuous glucose monitors, and acquiring the assets of shuttered insulin pump maker Asante.
Bigfoot also said it will be relocating to Milpitas, Calif., where Asante was headquartered. Read more
C.R. Bard said that the U.S. Centers for Medicare and Medicaid Services has improved the payment for Bard’s Lutonix drug-coated balloon catheter through the Medicare hospital outpatient prospective payment system.
The Murray Hill, N.J.-based company said that Medicare will now reimburse the full cost of its DCB device for percutaneous transluminal angioplasty, stenting, or atherectomy procedures. Read more